Report of chronic myeloid leukemia SMS Medical College Hospital, Jaipur

This is a retrospective analysis of patients of chronic myeloid leukemia (CML) registered and under treatment at the Leukemia Lymphoma Clinic at the Birla Cancer Center, SMS Medical College Hospital, Jaipur. Approximately, two-thirds of the patients are getting imatinib mesylate (IM) through the Gli...

Full description

Saved in:
Bibliographic Details
Main Authors: Hemant Malhotra, Rajesh Sharma, Yogender Singh, Hemant Chaturvedi
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2013-01-01
Series:Indian Journal of Medical and Paediatric Oncology
Subjects:
Online Access:http://www.ijmpo.org/article.asp?issn=0971-5851;year=2013;volume=34;issue=3;spage=177;epage=179;aulast=Malhotra
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849768364362170368
author Hemant Malhotra
Rajesh Sharma
Yogender Singh
Hemant Chaturvedi
author_facet Hemant Malhotra
Rajesh Sharma
Yogender Singh
Hemant Chaturvedi
author_sort Hemant Malhotra
collection DOAJ
description This is a retrospective analysis of patients of chronic myeloid leukemia (CML) registered and under treatment at the Leukemia Lymphoma Clinic at the Birla Cancer Center, SMS Medical College Hospital, Jaipur. Approximately, two-thirds of the patients are getting imatinib mesylate (IM) through the Glivec International Patient Assistance Program while the rest are on generic IM. In addition to comparison of hematological and molecular responses in the Glivec versus the genetic group, in this analysis, an attempt is also made to assess the socio-economic (SE) status of the patients and its effect on the response rates. Of the 213 patients studied, most (28.6%) are in the age group between 30 years and 40 years and the mean age of the patients in 39 years, a good decade younger that in the west. There is a suggestion that patients in lower SE class present with higher Sokal scores and with more disease burden. Possibly hematological responses are similar with both Glivec and generic IM. No comment can be made with regards to molecular response between the two groups as a significant number of patients in the Glivec arm (42%) do not have molecular assessment because of economic reasons. CML is a common and challenging disease in the developing world with patients presenting at an earlier age with more advanced disease. SE factors play a significant role in therapy and disease monitoring decision making and may impact on response rates and prognosis.
format Article
id doaj-art-bb36f9a552c54e44a516e9d0a7988027
institution DOAJ
issn 0971-5851
language English
publishDate 2013-01-01
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format Article
series Indian Journal of Medical and Paediatric Oncology
spelling doaj-art-bb36f9a552c54e44a516e9d0a79880272025-08-20T03:03:50ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58512013-01-0134317717910.4103/0971-5851.123723Report of chronic myeloid leukemia SMS Medical College Hospital, JaipurHemant MalhotraRajesh SharmaYogender SinghHemant ChaturvediThis is a retrospective analysis of patients of chronic myeloid leukemia (CML) registered and under treatment at the Leukemia Lymphoma Clinic at the Birla Cancer Center, SMS Medical College Hospital, Jaipur. Approximately, two-thirds of the patients are getting imatinib mesylate (IM) through the Glivec International Patient Assistance Program while the rest are on generic IM. In addition to comparison of hematological and molecular responses in the Glivec versus the genetic group, in this analysis, an attempt is also made to assess the socio-economic (SE) status of the patients and its effect on the response rates. Of the 213 patients studied, most (28.6%) are in the age group between 30 years and 40 years and the mean age of the patients in 39 years, a good decade younger that in the west. There is a suggestion that patients in lower SE class present with higher Sokal scores and with more disease burden. Possibly hematological responses are similar with both Glivec and generic IM. No comment can be made with regards to molecular response between the two groups as a significant number of patients in the Glivec arm (42%) do not have molecular assessment because of economic reasons. CML is a common and challenging disease in the developing world with patients presenting at an earlier age with more advanced disease. SE factors play a significant role in therapy and disease monitoring decision making and may impact on response rates and prognosis.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2013;volume=34;issue=3;spage=177;epage=179;aulast=MalhotraChronic myeloid leukemiachronic phaseJaipur
spellingShingle Hemant Malhotra
Rajesh Sharma
Yogender Singh
Hemant Chaturvedi
Report of chronic myeloid leukemia SMS Medical College Hospital, Jaipur
Indian Journal of Medical and Paediatric Oncology
Chronic myeloid leukemia
chronic phase
Jaipur
title Report of chronic myeloid leukemia SMS Medical College Hospital, Jaipur
title_full Report of chronic myeloid leukemia SMS Medical College Hospital, Jaipur
title_fullStr Report of chronic myeloid leukemia SMS Medical College Hospital, Jaipur
title_full_unstemmed Report of chronic myeloid leukemia SMS Medical College Hospital, Jaipur
title_short Report of chronic myeloid leukemia SMS Medical College Hospital, Jaipur
title_sort report of chronic myeloid leukemia sms medical college hospital jaipur
topic Chronic myeloid leukemia
chronic phase
Jaipur
url http://www.ijmpo.org/article.asp?issn=0971-5851;year=2013;volume=34;issue=3;spage=177;epage=179;aulast=Malhotra
work_keys_str_mv AT hemantmalhotra reportofchronicmyeloidleukemiasmsmedicalcollegehospitaljaipur
AT rajeshsharma reportofchronicmyeloidleukemiasmsmedicalcollegehospitaljaipur
AT yogendersingh reportofchronicmyeloidleukemiasmsmedicalcollegehospitaljaipur
AT hemantchaturvedi reportofchronicmyeloidleukemiasmsmedicalcollegehospitaljaipur